| Scientists Honored For Contributions To Cancer Fight |
| The American Cancer Society - the nation's leading voluntary health organization and largest non-governmental funder of cancer research and discovery - will present its highest honor, the Medal of Honor, to four Americans who have made outstanding contributions to the fight against cancer. This year's winners, who will receive their awards at a ceremony during the American Cancer Society's annual meeting in New York City, are: The Honorable Edward M.
11/21/2008
|
| Tumor Formation May Be Spurred By The Misreading Of Damaged DNA |
| The DNA in our cells is constantly under assault from oxygen, the sun's radiation and environmental stresses. Most of the time, our cells can repair the damage before it gets copied into a permanent mutation that could lead to cancer. Adding a wrinkle to our understanding of how cancers begin, scientists have found that cells can turn on tumor-promoting growth circuits as a result of misreading damaged DNA without copying it: a process called "transcriptional mutagenesis.
11/21/2008
|
| Tumors Fuelled By Lactic Acid |
| A team of researchers at Duke University Medical Center and the Université catholique de Louvain (UCL) has found that lactic acid is an important energy source for tumor cells. In further experiments, they discovered a new way to destroy the most hard-to-kill, dangerous tumor cells by preventing them from delivering lactic acid.
11/21/2008
|
| Survival Of Melanoma Cells Promoted By Gene Required For Radiation-Induced Protective Pigmentation |
| Scientists have new insight into the response of human skin to radiation and what drives the most aggressive and deadly form of skin cancer. The research, published by Cell Press in the November 21st issue of the journal Molecular Cell, may be useful in the design of new strategies for prevention of malignant melanoma. The process of tanning involves synthesis of the pigment melanin by skin cells known as melanocytes.
11/21/2008
|
| Oral Gefitinib As Effective As Injected Docetaxel For Survival Of Patients With Non-Small-Cell Lung Cancer (Interest Study) |
| Gefitnib is as effective a second-line treatment as docetaxel for patients with non-small cell* lung cancer. The INTEREST study, published in an Article in this week's edition of The Lancet, thus establishes gefitinib as a valid treatment option for people with this condition. The study was written by Dr Edward Kim, M. D. Anderson Cancer Center, Houston, Texas, USA and colleagues.
11/21/2008
|
| Type Of Breast Reconstruction Impacts Radiation Therapy Outcomes |
| For breast cancer patients who underwent a mastectomy who undergo radiation therapy after immediate breast reconstruction, autologous tissue reconstruction provides fewer long-term complications and better cosmetic results than tissue expander and implant reconstruction, according to a study in the November issue of the International Journal of Radiation Oncology*Biology*Physics, the official journal of the American Society for Therapeutic Radiology and Oncology.
11/21/2008
|
| Ortho Biotech Announces NDA Submission For Trabectedin For The Treatment Of Relapsed Ovarian Cancer |
| Ortho Biotech Products, L.P. announced the submission of a new drug application (NDA) to the U.S. Food and Drug Administration (FDA) for trabectedin when administered in combination with DOXIL(R) (doxorubicin HCI liposome injection)for the treatment of women with relapsed ovarian cancer (ROC). If approved, trabectedin combined with DOXIL will provide a new, non-platinum treatment option for these patients in the United States.
11/21/2008
|
| Pediatric Cancer : Alteration Of A Gene Causes Neuroblastoma |
| Olivier Delattre's team (Inserm Unit 830 "Genetics and Biology of Cancer") of the Institut Curie reveal in an article in the 16 October issue of Nature that alteration of the ALK gene is closely associated with the most frequent solid extracerebral tumor in children neuroblastoma. By studying the familial forms of this tumor, the researchers also conclude that ALK is a gene that predisposes to neuroblastoma. This discovery may allow the development of new treatments in neuroblastomas.
11/21/2008
|
| Bovie Medical Corporation Announces FDA 510(K) Clearance To Market SEER Tissue Resection Device |
| Bovie Medical Corporation (the "Company") (NYSE Alternext US: BVX), a manufacturer and marketer of electrosurgical products, today announced the Company received 510(k) clearance from the Food and Drug Administration (FDA) to market its SEER tissue resection device intended for initial use in liver oncology surgery. The SEER device uses conductive sintered steel as an electrode for radio frequency (RF) for cutting and coagulation.
11/20/2008
|
| Randomized Phase 2 Study Of IMC-A12 For HER2-Expressing Advanced Breast Cancer Commences Patient Enrollment |
| ImClone Systems Incorporated (NASDAQ: IMCL), a global leader in the development and commercialization of novel antibodies to treat cancer, today announced that its disease-directed randomized Phase 2 clinical trial of IMC-A12 in patients with previously treated HER2-expressing locally advanced or metastatic breast cancer has commenced patient enrollment. IMC-A12 is ImClone's fully human, IgG1 anti-insulin-like growth factor-1 receptor (IGF-1R) monoclonal antibody.
11/20/2008
|
| GenVec Announces Interim Survival Data In Pivotal Trial Of TNFeradeâ„¢ In Locally Advanced Pancreatic Cancer |
| GenVec, Inc. (Nasdaq:GNVC) announced today top-line results of an interim analysis from its ongoing Phase III Pancreatic Cancer Clinical Trial with TNFeradeâ„¢ (PACT) in patients with locally advanced pancreatic cancer. This interim analysis of overall survival, conducted after the 92nd death (one-third of total expected events), was designed to determine whether the study should continue and took place in the time frame originally estimated.
11/20/2008
|
| Relapsed Ovarian Cancer - Submitted New Drug Application To FDA For Trabectedin |
| PharmaMar announced today that Ortho Biotech Products, L.P. has submitted a new drug application (NDA) to the U.S. Food and Drug Administration (FDA) for trabectedin when administered in combination with DOXIL® (pegylated liposomal doxorubicin) for the treatment of women with relapsed ovarian cancer (ROC). If approved, trabectedin combined with DOXIL® will provide a new, non-platinum treatment option for these patients in the United States.
11/20/2008
|
| Higher Risk Of Certain Cancers Being Recorded In HIV-Positive People |
| Physicians in the U.S. are reporting a higher risk for certain types of cancers -- such as liver, head, neck and lung -- in people living with HIV/AIDS, raising concerns that a cancer epidemic is imminent in the population, the Baltimore Sun reports. According to the Sun, Meredith Shiels, a doctoral candidate at the
11/20/2008
|
| Ovarian Cancer Cells Destroyed By New Platinum-Phosphate Compounds |
| A new class of compounds called phosphaplatins can effectively kill ovarian, testicular, head and neck cancer cells with potentially less toxicity than conventional drugs, according to a new study published this week in the journal Proceedings of the National Academy of Sciences.
11/20/2008
|
| Gentium Provides An Update On The Phase 3 Treatment Trial Of Defibrotide For Severe Veno-Occlusive Disease |
| Gentium S.p.A. (NASDAQ: GENT) announced today interim results from an independent Data Safety Monitoring Board (DSMB) review of the Company's Phase 3 treatment trial of Defibrotide for Severe Veno-Occlusive Disease (VOD). The DSMB reported that in order for the study to be 80% powered to detect a p-value of .
11/20/2008
|
